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Abstract  
Background: Significance of pancreatic autoantibodies determined by using exocrine 
pancreas (PAB) and recombinant pancreas antigens (rPAB), as well as importance of 
autoantibodies against goblet cells (GAB) are not known in pediatric patients with 
inflammatory bowel disease (IBD). Our aim was to determine the complex analysis of PAB, 
rPAB, GAB, antibodies against Saccharomyces cerevisiae (ASCA), and perinuclear 
components of neutrophils (pANCA) in pediatric IBD patients. Moreover, association with 
NOD2/CARD15 and disease phenotype was determined. 
Methods: 152 pediatric patients (median age 13.9 years) with IBD [103 patients with Crohn’s 
disease (CD) and 49 patients with ulcerative colitis (UC)] and 104 controls were included. 
Serum autoantibodies were determined by indirect immunofluorescens assay. 
NOD2/CARD15 variants were tested by polymerase chain reaction/restriction fragment 
length polymorphism. 
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Results: The presence of PAB and rPAB was significantly higher in CD (34% and 35.9%) 
and in UC (20.4% and 24.5%) compared to pediatric control cohort (0% and 0%, p<0.0001). 
In addition, GAB positivity was significantly increased in patients with UC in comparison to 
CD and controls, respectively (UC, 12.2%, CD, 1.9%, controls, 1.9%, p=0.02). Specificity of 
PAB and rPAB was 100%, however, sensitivity was low. The combination of PAB and/or 
ASCA/pANCA improved the sensitivity of serological markers in CD (87.4%) and in UC 
(79.6%); specificities were 89.3% and 93.2%, respectively. Pancreatic autoantibodies (PAB, 
rPAB) and GAB were not related to clinical presentation, medical therapy or need for surgery 
in CD or in UC. 
Conclusions: Pancreatic autoantibodies and GAB were specific for IBD but the sensitivity 
was limited as well as there was lack of correlation with clinical phenotype. Combinations of 
these antibodies have shown increased sensitivity, therefore, it may be recommended in the 
diagnostic procedure of IBD. 
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Introduction 
Inflammatory bowel diseases (IBDs), Crohn’s disease (CD) and ulcerative colitis (UC) are 
chronic relapsing and remitting disorders of the gastrointestinal tract. The pathogenesis of 
IBD is complex and multifactorial. Current evidence suggests that IBD results from an 
aberrant immune response and loss of tolerance to the normal intestinal flora, leading to 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 4
chronic inflammation of the gut in a genetically susceptible host (1). This hypothesis is 
supported by the occurrence of antibodies directed to microbial antigens and by the 
identification of NOD2/CARD15, as susceptibility genes to CD (2). Besides genetic 
predisposition and environmental factors, autoimmune mechanisms are suggested to play a 
vital part in the pathogenesis of IBD. The search for the underlying trigger of the abnormal 
intestinal inflammation characteristics of IBD has led to the discovery of antibodies present 
specifically in the blood of patients with CD and/or UC. Several autoantibodies have been 
described in IBD. 
 Relatively low prevalence of exocrine pancreas antibodies (PAB) was detected in 
adult patients with CD (27-39%) using indirect immunofluorescence (IIF) (3,4). However, 
increased prevalence of PAB has been found in un-affected first-degree relatives of IBD 
patients, suggesting a genetic origin of these antibodies (5). The determination of 
autoantibodies against exocrine pancreas by IIF using human cells transfected with the 
recently identified proteoglycans CUZD1 and GP2 as recombinant target antigens 
(recombinant pancreas antigen 1 and 2: rPAg1 and rPAg2) represents a new dimension in the 
serological diagnosis of IBD (6,7). The studies conducted in adult patients provided 
conflicting data regarding association between PAB and CD phenotype (4,8,9). 
 Autoantibodies against intestinal goblet cells (GAB) have previously been described 
in UC with a prevalence of 28-30% and in 20% of first-degree relatives to IBD patients 
(3,10). Recent studies, however, suggested a much lower prevalence in both diseases (4,11). 
Moreover, PAB, rPAB and GAB have not been examined in a large cohort of pediatric IBD, 
and data on the specificity and sensitivity are contradictory in adult IBD. 
 The two most intensively studied conservative antibodies are autoantibodies to 
neutrophils [perinuclear anti-neutrophil cytoplasmic antibodies (pANCA)], primarily 
associated with UC and anti-Saccharomyces cerevisiae antibodies (ASCA), primarily 
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associated with CD (2,12). In pediatric IBD the sensitivity/specificity of pANCA in UC 
ranged between 57-83%, and 65% to 97% respectively, whereas in CD, ASCA showed a 
sensitivity/specificity in the range of 44% to 76%, and 88% to 95%, respectively (13,14). 
ASCA positivity or high titers are associated with a complicated disease behavior (penetrating 
or stenosing disease) and could be useful markers for predicting need for surgery also in 
pediatric patients (15-17). PANCA is noted for its association with „UC-like” CD phenotype 
(18,19). 
 The clinical importance of PAB and GAB is understudied in pediatric IBD patients. 
The aim of our study was to determine the prevalence of PAB, rPAB, GAB, ASCA, and 
pANCA in patients with pediatric-onset IBD. In addition, we assessed the association 
between antibody profile and NOD2/CARD15 status, clinical presentation, response to 
treatment and extraintestinal manifestations. 
 
Patients and methods 
Patients 
Our study included 103 consecutive patients with pediatric-onset CD [male/ female 
(m/f) ratio: 63/40, median age: 13.9 years (range: 5.3-19.6 years)], 49 patients with pediatric-
onset UC [m/f ratio: 22/27, median age: 12.5 years (range: 6-19.7 years)], and 104 age-and 
sex-matched controls. The diagnosis of IBD was based on clinical, radiologic, endoscopic and 
histological criteria. Disease activity was evaluated according to the Pediatric Crohn’s 
Disease Activity Index (PCDAI) in children with CD and according to the Pediatric 
Ulcerative Colitis Index (PUCAI) for the UC group (21,22). Activity index >30 is defined as 
a moderate-severe disease, the index between 11-30 indicates a mild disease, and the index 
≤10 refers to an inactive disease. 
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 Age, age at onset, presence of extraintestinal manifestation (EIM); arthritis, ocular 
manifestations, skin lesions, and hepatic manifestations, frequency of flare-ups (frequent flare 
up:>1/year), therapeutic effectiveness (e.g.: need for steroid and/or immunosuppressive 
therapy) steroid resistance need for surgery (resection), the presence of familial IBD were 
collected by the clinical investigator reviewing the medical charts and completing a 
questionnaire. The disease phenotype (age at onset, duration, location, and behavior) was 
determined according to the Montreal Classification. In this study, complicated disease 
behavior in CD patients was defined as stricturing or penetrating behavior during follow-up. 
Only patients with a confirmed diagnosis for more than 1 year were enrolled.  
 Blood samples were obtained prospectively for PAB, rPAB, GAB, ASCA, and 
pANCA. At the time of taking blood samples, patients had a clinical assessment, including 
calculation of clinical disease activity scores. Sera for serological markers determination were 
coded to maintain blinding. After serum separation, blood samples were stored at -80 °C until 
further analysis. 
 The study protocol was approved by the Ethical and Science Committee of the 
Semmelweis University. Each parent of the children was informed about the nature of the 
study and signed the informed consent form. 
 
Antibody assays for PAB, rPAB, GAB, ASCA, and ANCA 
Presence of PAB, rPAB, GAB, ASCA and ANCA was determined in an commercially 
available IIF assay (EUROIMMUN AG, Luebeck, Germany) according to the manufacturers’ 
instructions. For IIF coated cover glasses with several biological substrates were cut into 
millimeter-sized fragments (BIOCHIPs, EUROIMMUN AG)  and used side by side in the 
same reaction field, giving the opportunity to investigate one serum on several tissues or 
prepared cells: PAB: monkey pancreas, recombinant pancreas antigen 1 (rPAg1) CUZD1 and 
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recombinant pancreas antigen 2 (rPAg2) GP2: human transfected cells, non-transfected cells 
(control), GAB: human intestinal goblet cell culture, ASCA: Saccharomyces cerevisiae fungal 
smear, ANCA: ethanol (EOH)-fixed and formalin (HCHO)-fixed human granulocytes. Sera 
were incubated at a 1:10 dilution (ASCA IgG: 1:1000, ASCA IgA: 1:100) in phosphate-
buffered saline (PBS)/ Tween for 30 min. After washing with the buffer, slides were then 
incubated with fluorescein-labelled goat antihuman IgG or IgA antibodies for another 30 
minutes. After further washing evaluation and classification of the patterns was performed 
under ultraviolet light (UV) using fluorescence microscope (EUROIMMUN LED, EUROStar 
Bluelight, EUROIMMUN AG, Luebeck, Germany). Sera that showed specific fluorescence 
patterns were classified as follows:  
1) Two relevant patterns against pancreas acinus cells can be found: a reticulo-glanular (type 
1) and a drop-like fluorescence (type 2). Antibodies against rPAg1 (CUZD1) resulted in a 
reticulo-granular, while antibodies against rPAg2 (GP2) resulted in a drop-like pattern. 2) 
GAB positivity can be detected as a cloudy fluorescence with indistinct boundary on intestinal 
goblet cells. 3) If ASCA were present, the smeared globular yeasts on the reaction fields 
fluoresced clearly in their entirety. 4) Using ethanol-fixed granulocytes two basic ANCA 
patterns were detectable: a granular fluorescence which is distributed evenly over the entire 
cytoplasm, leaving the cell nuclei free (cytoplasmic type, cANCA) or a fluorescence around 
the cell nuclei (perinuclear type, pANCA). Interference by antinuclear antibodies, which may 
mimic the pANCA pattern, was excluded by evaluation on HEp-2 cells, liver tissue of 
primates and formalin-fixed granulocytes. All positive sera were titrated to end-point. 
 
Detection of NOD2/CARD15 mutations 
Genomic DNA was isolated from whole blood using the QIAamp DNA Blood Mini Kit 
(QIAGEN, Germany). The three NOD2/CARD15 variants, Arg702Trp, Gly908Arg, 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 8
Leu1007fs, were typed using polymerase chain reaction/restriction fragment length 
polymorphism as previously described (22). NOD2/CARD15 variants were detected by 
denaturing high-performance liquid chromatography (dHPLC, Wave DNA Fragment Analysis 
System, Transgenomic, UK). Sequence variation, observed in the dHPLC profile, was 
sequenced on both strands to confirm the alteration. Sequencing reactions were performed 
with the ABI BigDye Terminator Cycle Sequencing Kit v1.1 (Applied Biosystems, Foster 
City, CA) and samples were sequenced on an ABI Prism 310 Genetic Analyzer (Applied 
Biosystems). Genotyping was carried out at the National Haematology and Immunology 
Institute, Budapest, Hungary.  
 
Statistical Analysis 
Statistical analysis was carried out using Graph Pad Prism 5 (GraphPad, San Diego CA, 
USA). The presence of ASCA, pANCA, PAB, rPAB, and GAB were compared between the 
IBD and control cohorts, as well as within subgroups of IBD patients using χ2-test and 
Fisher’s exact test. The differences of age between in subgroups of patients were assessed by 
Mann-Whitney-test. Logistic regression analysis was also performed to assess the complex 
associations between clinical phenotype and the serology profile. A p value of <0.05 was 
considered as significant. 
 
Results 
Characteristics of patients with IBD 
The clinical phenotype of CD and UC patients is shown in Table 1. Median age at diagnosis 
was 13.9 years. Fifty-one percent of CD patients and 50% of UC patients had active disease, 
whereas 49% of CD patients and 50% of UC patients were in remission at the time of taking 
blood samples. Forty pediatric CD patients (38.8%) developed penetrating and /or stricturing 
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disease after a median follow-up of 18 months and 9.7% underwent surgery. App. 80% of 
patients were treated with steroids at some point during their disease and the majority (72.1%) 
was treated with azathioprine. Twenty percent of CD patients received infliximab, 40 % had 
remission or fistula closure 60% had partial remission or partial fistula closure.. 
 
Diagnostic accuracy of PAB, rPAB, and GAB and association with disease phenotype in 
CD and UC 
Sensitivity and specificity data for PAB, rPAB and GAB are given in Table 2.  
The presence of PAB and rPAB (IgA or IgG) antibodies was significantly higher in CD (34% 
and 35.9%) and UC (20.4% and 24.5%) compared to controls (0% and 0%, p<0.0001). The 
combination of PAB and/or ASCA/pANCA improved sensitivity of serological markers in 
both CD (87.4%) and UC (79.6%). Specificities were 89.3% and 93.2%, respectively. The 
positive predictive value (PPV) was 89.1% in CD for the combination of the markers and 
negative predictive value (NPV) was 87.6% (in UC, PPV, 93.2%, NPV, 82.2%). The accuracy 
of serologic antibodies is shown in Table 2. A strong association was observed between the 
reticulo-granular pancreatic IIF pattern and the reactivity of CUZD1 transfected cells (CD, 26 
cases, UC, 8 cases) as well as between the droplet pattern and GP2 reactivity (CD, 24 cases, 
UC, 3 cases). 1 sera showed positive CUZD1 and 3 sera positive GP2 reactions (CD, 1, UC, 
2), but no signal with tissue. 
GAB positivity was significantly higher in patients with UC compared to CD and controls, 
respectively (UC, 12.2%, CD, 1.9%, controls: 1.9%, p=0.02). 
The presence of PAB, rPAB, and GAB was not associated to clinical presentation, medical 
therapy, need for surgery or extraintestinal manifestations in either CD or in UC. The PAB 
and rPAB positivity was numerically higher in patients with colonic (28.6% and 27%) and 
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ileocolonic (60% and 59.4%) CD than in ileal disease (11.4% and 13.5%) [Table 3], however 
the difference was not statistically significant. 
 
Diagnostic accuracy of ASCA and pANCA and association with disease phenotype in 
CD and in UC 
Of the 103 CD patients studied 72.8% were ASCA positive (either IgA or IgG). Specifically, 
63.1% were positive for ASCA IgA, 66.9% for ASCA IgG, and 60.2% for both ASCA IgA 
and IgG. The presence of ASCA (either IgA or IgG) was significantly higher in CD (72.8%) 
compared to UC (26.5%), and control (4.8%) patients. 
ASCA positivity was associated with complicated disease behavior (p=0.0003) [stenosing 
(p=0.02) and/or penetrating disease behavior (p=0.0003)] and perianal complications (p=0.01) 
in CD. Association with location in patients with CD was not found [Table 4]. The frequency 
of stenosing and penetrating disease, and ileocolonic involvement increased with increasing 
number of immune responses, whereas inflammatory behavior (B1) showed inverse 
correlation with the number of ASCA [Table 5] There was no significant difference with 
regard to the need for surgery between ASCA positive and ASCA negative patients (need for 
surgery: 12% vs. 3.6%). ASCA was not associated with medical therapy and extraintestinal 
manifestations.  
ASCA positivity was found in 13 UC patients (26.5%), however 7 of these patients had 
progressive sclerosing cholangitis (PSC). 
PANCA were detected in 38 (77.5%) of 49 UC and in 34 (33%) of 103 CD patients. The 
presence of pANCA was not associated with clinical presentation, medical therapy, need for 
surgery or extraintestinal manifestations neither in CD nor in UC.  
 
NOD2/CARD15 genotype, serum antibodies and phenotype in CD 
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NOD2/CARD15 genotypes were known for 43 CD patients. Mutations of NOD2/CARD15 
were detected in 13 (30.2%) CD patients. There was no association of ASCA, PAB, rPAB and 
pANCA antibody status to NOD2/CARD 15 genotype. Three NOD2 carriers were PAB and 
ASCA negative, and two NOD2 carriers were PAB, ASCA and pANCA negative. NOD2 
mutations were not related to age at onset, disease location and disease behavior. 
Nevertheless, NOD2 variants were significantly related to steroid refractory disease and 
administration of infliximab. 
 
Discussion 
This is the first report to assess the diagnostic value of PAB, rPAB and GAB as well as 
relevant phenotype-serotype associations in large cohort of patients with pediatric-onset IBD. 
Furthermore, we investigated the accuracy in combination with ASCA and pANCA, and 
NOD2/CARD15 mutations. In the present study PAB positivity in CD (34%) was similar to 
previous reports from in adult patients. The prevalence of rPAB was numerically higher than 
PAB. Prevalence of 27-39% of PAB has been found in adult CD patients, compared with only 
0-5 % in UC patients (3,9,23). Stöcker et al. reported that PAB could be determined only in 
the serum of patients with CD (3). However, other studies found a much higher prevalence of 
PAB in UC (4,8,24) in accordance with our results (20.4%). Even though the specificity of 
PAB for CD and UC is high, their sensitivity is low. However, sensitivity can be significantly 
increased with combinations of different antibodies (see below). Recent studies have 
demonstrated that GP2 is expressed on the apical surface of intestinal membranous cells of 
the follicle-associated epithelium, and is essential for host-microbial interaction and the 
initiation of bacteria-specific mucosal immune responses (24,25). 
 There are conflicting results of association between PAB and CD phenotype in adult 
cohorts. In a Belgian study PAB was negatively associated with stricturing disease behavior 
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in CD (5). In contrast, in other European studies, an increased prevalence of PAB was 
observed in patients with stricturing or penetrating phenotypes (4,9,26). Lakatos et al. 
reported association between PAB positivity and perianal disease and extraintestinal 
manifestations (4). In a French study PAB correlated with early onset of disease in CD (23). 
In the present study pancreatic autoantibodies were not related to clinical presentation, 
medical therapy, need for surgery or extraintestinal manifestations in CD or in UC. 
Autoantibodies against different colonic antigens have been found in patients with 
UC; for example GAB. In previous studies GAB have been detected in adult UC patients, the 
prevalence was 28-30% (3,10). In contrast, other studies suggested a much lower prevalence 
in both diseases (4,11). Probably, these differences are due to methodological differences, 
such as in ELISA antigen substrates and in evaluation of fluorescence patterns. GAB 
produces mucin that has multiple functions: it serves as a lubricant, provides nonspecific 
protection against unwanted microbial agents, and hosts the normal bacterial flora. Through 
complicated and strictly regulated glycosylation, mucins act as a decoy in binding a range of 
different microbes and thereby maintaining a normal intestinal flora. The significance of these 
antibodies, however has not been established and its remains unclear. 
In agreement with the results published by Lakatos et al. and Lawrence et al. in our study the 
prevalence of GAB in our UC group was lower (12.2%) than previously reported (3,10). One 
explanation for the lower prevalence of GAB in our study may be the younger age of the 
patients. In concordance with earlier data (4) we could not demonstrate any association 
between the presence of GAB and clinical presentation, medical therapy, need for surgery or 
extraintestinal manifestations in UC patients. Consequently, the clinical utility of GAB for 
diagnostic purposes in pediatric IBD is limited. 
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In the present study the prevalence of ASCA in CD (72.8%) was similar to previous 
pediatric reports (44%-76%) (13-15,27). In concordance with published data we observed 
association between ASCA positivity and stenosing and penetrating behavior (16,23,28,29). 
ASCA positivity in our patients with UC was higher compared with earlier reports, perhaps 
due to the relatively higher proportion of patients with PSC. Of note, in an Italian study 
ASCA reactivity was detected in 44% of PSC patients (30). In the present study, the presence 
of ASCA in UC patients without PSC was found similar to other studies (31,32). 
The prevalence of pANCA in our UC and CD patients (UC:77.5%, CD:33%) was 
comparable to earlier reports (57-83%) (13,14,32). Although pANCA has been established as 
an UC specific marker, approximately 25% of all CD patients also express pANCA (18). 
Several studies have suggested that pANCA expression is significantly higher in colonic CD 
(17,19,33), but others have been unable to confirm this finding (34). In the present study we 
did not observe any correlation between pANCA positivity and colonic CD. 
In addition, we evaluated the diagnostic accuracy of combining markers. In 
concordance with previous data (11) in the present study the specificity of PAB was 100%, 
however, sensitivity was low (CD, 34%, UC, 20.4%). The sensitivity increased for 
combinations (e.g. PAB, ASCA and pANCA for CD (87.4%) as well as PAB and pANCA for 
UC (79.6%)). In combinations the specificity for CD was 89.3% and for UC was 94.2%. 
Associations between NOD2 variants and complicated disease course, earlier time to 
surgery in children with CD were reported (35,36). In the present study we could not 
demonstrate any association of NOD2/CARD15 genotype, serum antibodies and phenotype in 
CD. However, in accordance with the results of Roesler et al. (37) we found an association 
between NOD2 variants and need for more intensive therapy (steroid refractory disease and 
infliximab use) in our CD cohort. 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 14
In conclusion, pancreatic autoantibodies (PAB, rPAB) and GAB were specific for IBD 
but the sensitivity was limited as well as they were not associated to clinical phenotype. 
Combinations of these antibodies with conventional serology markers are associated with 
increased sensitivity, therefore, the use of combinations may be recommended in the 
diagnostic work-up of selected IBD cases. 
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Table 1. Clinical data of IBD patients 
 CD 
n=103 
UC 
n=49 
Male/female 63/40 (61/39%) 22/27 (45/55%) 
Age (y) 13.9 (range:5.3-19.6) 12.5 (range:6-19.7) 
Age at presentation (y) 10.8 (range:2-18) 10.2 (range:1.7-18) 
Duration (y) 1.5 (range:0.5-11) 2.3 (range:0.5-13.4) 
Location   
 Ileum (L1): 17/103 (16.5%) Proctitis (E1): 4/49 (7.1%) 
 Colon (L2): 30/103 (29.1%) Left sided (E2):15/49 (35.8%) 
 Ileocolon (L3): 56/103 (54.4%) Extensive (E3): 33/49 (57.1%) 
 Upper GI (+L4): 24/103 (23.3%)  
Behavior   
 Inflammatory (B1):  
63/103 (61.2%) 
 
 Stricturing (B2): 18/103 (17.5%)  
 Penetrating (B3): 27/103 (26.2%)  
   
Perianal disease 21/103 (20.4%)  
Frequent relapse 43/103 (41.7%) 22/49 (48.9%) 
Surgery 10/10385 (9.7%) 1/49 (2%) 
NOD2/CARD15 carrier 
(n=43) 
13/43 (30.2%)  
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Table 2. Diagnostic value of serological markers in children with IBD 
  Sensitivity 
(%) 
Specificity 
(%) 
PPV  
(% ) 
NPV  
(%) 
P value 
rCD vs. 
controls 
n=103 
ASCA 72.8 95.2 93.8 77.8 <0.0001 
PAB 34.0 100 100 60.2 <0.0001 
rPAB 35.9 100 100 60.9 <0.0001 
pANCA 33.0 94.2 85.1 58.4 <0.0001 
GAB 1.9 98.1 50.0 50.0 1.0000 
PAB and/or ASCA 79.6 95.2 94.3 82.3 <0.0001 
rPAB and/or ASCA 79.6 95.2 94.3 82.3 <0.0001 
PAB and/or ASCA 
and/or pANCA 
87.4 89.3 89.1 87.6 <0.0001 
rPAB and/or ASCA 
and/or pANCA 
87.4 89.3 89.1 87.6 <0.0001 
PAB and ASCA (both) 29.1 100 100 58.5 <0.0001 
rPAB and ASCA (both) 31.1 100 100 59.2 <0.0001 
PAB and /or ASCA/ 
pANCA- 
53.4 95.2 91.8 67.1 <0.0001 
rPAB and /or ASCA/ 
pANCA- 
53.4 95.2 91.8 67.1 <0.0001 
PAB+/ASCA+/pANCA- 21.4 100 100 56.0 <0.0001 
rPAB+/ASCA+/pANCA- 23.3 100 100 56.6 <0.0001 
ASCA+/pANCA- 51.5 95.2 91.5 66.2 <0.0001 
       
UC vs. pANCA 77.5 94.2 93.0 80.9 <0.0001 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
 22
controls 
n=49 
GAB 12.2 98.1 86.5 52.8 0.0196 
PAB 20.4 100 100 55.6 <0.0001 
rPAB 24.5 100 100 57.0 <0.0001 
ASCA 26.5 95.2 84.7 56.4 0.0014 
ASCA* 16.3 95.2 77.3 53.2 0.4419 
PAB and/or pANCA 79.6 94.2 93.2 82.2 <0.0001 
rPAB and/or pANCA 79.6 94.2 93.2 82.2 <0.0001 
PAB and/or pANCA 
and/or GAB 
79.6 94.2 93.2 82.2 <0.0001 
rPAB and/or pANCA 
and/or GAB 
79.6 94.2 93.2 82.2 <0.0001 
GAB+/pANCA+ 12.2 98.1 86.5 52.8 0.0136 
PAB+/pANCA+ 18.4 100 100 55.1 <0.0001 
rPAB+/pANCA+ 22.4 100 100 56.3 <0.0001 
GAB+/PAB+/pANCA+ 4.1 100 100 51.0 0.1011 
*Diagnostic value of ASCA antibodies in UC patients without PSC 
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Table 3. PAB and rPAB positivity (%) in patients with CD (n=103) in  
association with disease location and behaviour  
 
No statistically significant differences were noted. 
 
 
 
 
 
 
 
 
 
 
 
 PAB+ (%) 
n=35 
PAB- (%) 
n=68 
rPAB+ (%)
n=37 
rPAB- (%) 
n=66 
Location     
Ileum (L1) 4 (11.4%) 13 (19.1%) 5 (13.5%) 12 (18.2%) 
Colon (L2) 10 (28.6%) 20 (29.4%) 10 (27%) 20 (30.3%) 
Ileocolon (L3) 21 (60%) 35 (51.5%) 22 (59.4%) 34 (51.5%) 
Upper GI (+L4) 8 (22.9%) 16 (23.5%) 9 (24.3%) 15 (22.7%) 
Behavior     
Inflammatory (B1) 22 (62.9%) 41 (60.3%) 23 (62.1%) 40 (60.6%) 
Stenosing (B2) 7 (20%) 11 (16.2%) 7 (18.9%) 11 (16.6%) 
Penetrating (B3) 6 (17.1%) 21 (31%) 7 (18.9%) 206 (30.3%)
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Table 4. ASCA positivity (%) in patients with CD (n=103) in association  
with disease location, behavior and need for surgery 
 ASCA+ 
n=75 
ASCA- 
n=28 
P value 
 
OR  
 
95% Cl  
 
Location      
L1 (n=17) 12 (16%) 5 (17.9%) 0.77a 0.87 0.27-2.7 
L2 (n=30) 19 (25.3%) 11 (39.3%) 0.22b 1.91 0.76-4.78 
L3 (n=56) 44 (58.6%) 12 (42.8%) 0.18c 1.89 0.78-4.55 
L4 (n=24) 20 (26.6%) 4 (14.3%) 0.29d 0.29 0.67-7.07 
Behavior      
B1 (n=63) 38 (50.6%) 25 (89.3%) 0.0003e 0.12 0.03-0.44 
B2 (n=18) 16 (21.3%) 2 (7.1%) 0.02f 5.2 1.11-24.91 
B3 (n=27) 26 (34.6%) 1 (3.6%) 0.0003g 17.1 2.17-134.3 
Perianal disease 20 (26.6%) 1 (3.6%) 0.01 9.8 1.25-77.1 
Surgery 9 (12%) 1 (3.6%) 0.27 3.7 0.45-31.47 
aL1 vs.L2+L3, bL2 vs.L1+L3, cL3 vs.L1+L2, dL4 vs.non L4, dB1 vs.B2 and/or B3, fB2 vs. B1, 
gB3 vs. B1 
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Table 5. Disease characteristics in CD patients in relation to the number of responses to 
ASCA 
 Serological Marker (ASCA) 
Positivity 
Statistical analysis 
 
Clinical Phenotype 
 
(n=103) 
0 
 
(n=28) 
1 
 
(n=13) 
2 
 
(n=62) 
P value 
(0 vs.2) 
OR  
(0 vs.2) 
95% Cl  
(0 vs.2) 
Ileum (L1) 5 (17.2%) 2 (15.4%) 10 (16.1%) 1.0 1.13 0.34-3.68 
Colon (L2) 11 (37.9%) 2 (15.4%) 17 (27.4%) 0.33 1.71 0.66-4.39 
Ileocolon (L3) 12 (41.3%) 9 (69.2%) 35 (56.4%) 0.02 0.35 0.15-0.83 
Inflammatory (B1) 25 (89.3%) 9 (69.2%) 29 (46.8%) 0.0001 9.4 2.59-34.7 
Stenosing (B2) 2 (7.1%) 3 (23%) 13 (21%) 0.03 0.17 0.03-0.86 
Penetrating (B3) 1 (3.6%) 3 (23.1%) 23 (37.1%) 0.0002 0.05 0.006-0.4 
Perianal 
complications 
1 (3.6%) 4 (30.8%) 16 (25.8%) 0.01 0.10 0.01-0.84 
Surgery 1 (3.6%) 1 (7.7%) 8 (12.9%) 0.26 0.25 0.03-2.1 
 
 
 
